{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:19:12Z","timestamp":1788898752893,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40744-025-00804-3","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T20:28:30Z","timestamp":1763152110000},"page":"115-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["On-Label Treatment Persistence Through 24\u00a0Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Schwartzbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Yokoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"804_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7:59. https:\/\/doi.org\/10.1038\/s41572-021-00293-y.","journal-title":"Nat Rev Dis Primers"},{"key":"804_CR2","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1002\/art.41741","volume":"73","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, Crowson CS, Bekele D, et al. The epidemiology of psoriatic arthritis over five decades: a population-based study. Arthritis Rheumatol. 2021;73:1878\u201385. https:\/\/doi.org\/10.1002\/art.41741.","journal-title":"Arthritis Rheumatol"},{"key":"804_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054901","volume":"24","author":"AB Azuaga","year":"2023","unstructured":"Azuaga AB, Ram\u00edrez J, Ca\u00f1ete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24:4901. https:\/\/doi.org\/10.3390\/ijms24054901.","journal-title":"Int J Mol Sci"},{"key":"804_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379. https:\/\/doi.org\/10.1038\/s41584-022-00798-0.","journal-title":"Nat Rev Rheumatol"},{"key":"804_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71:5\u201332. https:\/\/doi.org\/10.1002\/art.40726.","journal-title":"Arthritis Rheumatol"},{"key":"804_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83:706\u201319. https:\/\/doi.org\/10.1136\/ard-2024-225531.","journal-title":"Ann Rheum Dis"},{"key":"804_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395:1115\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(20)30265-8.","journal-title":"Lancet"},{"key":"804_CR8","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395:1126\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(20)30263-4.","journal-title":"Lancet"},{"key":"804_CR9","unstructured":"Tremfya. Package insert. Janssen Biotech, Inc; 2025."},{"key":"804_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/rheumatology\/keac375","volume":"62","author":"LC Coates","year":"2023","unstructured":"Coates LC, Ritchlin CT, Gossec L, et al. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford). 2023;62:606\u201316. https:\/\/doi.org\/10.1093\/rheumatology\/keac375.","journal-title":"Rheumatology (Oxford)"},{"key":"804_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1\u00a0year results of a phase\u00a0III randomised study of patients who were biologic-naive or TNF\u03b1 inhibitor-experienced. RMD Open. 2021;7:e001457. https:\/\/doi.org\/10.1136\/rmdopen-2020-001457.","journal-title":"RMD Open"},{"key":"804_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41927-024-00375-w","volume":"8","author":"LC Coates","year":"2024","unstructured":"Coates LC, Rahman P, Mease PJ, et al. Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase\u00a03, randomized, double-blind, placebo-controlled study. BMC Rheumatol. 2024;8:6. https:\/\/doi.org\/10.1186\/s41927-024-00375-w.","journal-title":"BMC Rheumatol"},{"key":"804_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003977","volume":"10","author":"LC Coates","year":"2024","unstructured":"Coates LC, Gossec L, Zimmermann M, et al. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase\u00a03, randomised, double-blind, placebo-controlled study. RMD Open. 2024;10:e003977. https:\/\/doi.org\/10.1136\/rmdopen-2023-003977.","journal-title":"RMD Open"},{"key":"804_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18094872","volume":"18","author":"E Menditto","year":"2021","unstructured":"Menditto E, Cahir C, Malo S, et al. Persistence as a robust indicator of medication adherence-related quality and performance. Int J Environ Res Public Health. 2021;18:4872. https:\/\/doi.org\/10.3390\/ijerph18094872.","journal-title":"Int J Environ Res Public Health"},{"key":"804_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40801-024-00428-z","volume":"11","author":"JA Walsh","year":"2024","unstructured":"Walsh JA, Lin I, Zhao R, et al. Comparison of real-world on-label treatment persistence in patients with psoriatic arthritis receiving guselkumab versus subcutaneous tumor necrosis factor inhibitors. Drugs Real World Outcomes. 2024;11:487\u201399. https:\/\/doi.org\/10.1007\/s40801-024-00428-z.","journal-title":"Drugs Real World Outcomes"},{"key":"804_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.18553\/jmcp.2023.29.1.90","volume":"29","author":"C Xu","year":"2023","unstructured":"Xu C, Ferrante SA, Fitzgerald T, Pericone CD, Wu B. Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals. J Manag Care Spec Pharm. 2023;29:90\u2013100. https:\/\/doi.org\/10.18553\/jmcp.2023.29.1.90.","journal-title":"J Manag Care Spec Pharm"},{"key":"804_CR17","unstructured":"Humira. Package insert. AbbVie; 2024."},{"key":"804_CR18","unstructured":"Cimzia. Package insert. UCB, Inc.; 2022."},{"key":"804_CR19","unstructured":"Enbrel. Package insert. Amgen Inc.; 2024."},{"key":"804_CR20","unstructured":"Simponi. Package insert. Janssen Biotech, Inc; 2019."},{"key":"804_CR21","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s13555-023-00910-6","volume":"13","author":"T Fitzgerald","year":"2023","unstructured":"Fitzgerald T, Zhdanava M, Pilon D, et al. Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA. Dermatol Ther (Heidelb). 2023;13:1053\u201368. https:\/\/doi.org\/10.1007\/s13555-023-00910-6.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"804_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy201","volume":"188","author":"F Li","year":"2019","unstructured":"Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol. 2019;188:250\u20137. https:\/\/doi.org\/10.1093\/aje\/kwy201.","journal-title":"Am J Epidemiol"},{"key":"804_CR23","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","volume":"323","author":"LE Thomas","year":"2020","unstructured":"Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020;323:2417\u20138. https:\/\/doi.org\/10.1001\/jama.2020.7819.","journal-title":"JAMA"},{"key":"804_CR24","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"P Austin","year":"2009","unstructured":"Austin P. A standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228\u201334. https:\/\/doi.org\/10.1080\/03610910902859574.","journal-title":"Commun Stat Simul Comput"},{"key":"804_CR25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40744-023-00582-w","volume":"10","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Ogdie A, Tesser J, et al. Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas psoriatic arthritis\/spondyloarthritis registry. Rheumatol Ther. 2023;10:1479\u2013501. https:\/\/doi.org\/10.1007\/s40744-023-00582-w.","journal-title":"Rheumatol Ther"},{"key":"804_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/acr2.11523","volume":"5","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Deodhar A, Boehncke WH, et al. Multidomain efficacy and safety of guselkumab through 1\u00a0year in patients with active psoriatic arthritis with and without prior tumor necrosis factor inhibitor experience: analysis of the phase\u00a03, randomized, placebo-controlled DISCOVER-1 study. ACR Open Rheumatol. 2023;5:149\u201364. https:\/\/doi.org\/10.1002\/acr2.11523.","journal-title":"ACR Open Rheumatol"},{"key":"804_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase\u00a0III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74:475\u201385. https:\/\/doi.org\/10.1002\/art.42010.","journal-title":"Arthritis Rheumatol"},{"key":"804_CR28","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.18553\/jmcp.2021.27.8.1106","volume":"27","author":"Y Jin","year":"2021","unstructured":"Jin Y, Chen SK, Lee H, Landon JE, Merola JF, Kim SC. Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis. J Manag Care Spec Pharm. 2021;27:1106\u201317. https:\/\/doi.org\/10.18553\/jmcp.2021.27.8.1106.","journal-title":"J Manag Care Spec Pharm"},{"key":"804_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database. JAMA Dermatol. 2022;158:513\u201322. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0364.","journal-title":"JAMA Dermatol"},{"key":"804_CR30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/ard-2022-222879","volume":"82","author":"L Gossec","year":"2023","unstructured":"Gossec L, Siebert S, Bergmans P, et al. Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Ann Rheum Dis. 2023;82:496\u2013506. https:\/\/doi.org\/10.1136\/ard-2022-222879.","journal-title":"Ann Rheum Dis"},{"key":"804_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002681","volume":"8","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Hoisnard L, Bastard L, Sbidian E, Claudepierre P. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS). RMD Open. 2022;8:e002681. https:\/\/doi.org\/10.1136\/rmdopen-2022-002681.","journal-title":"RMD Open"},{"key":"804_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Roseno NAL, Aagaard D, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis\u2014a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151979.","journal-title":"Semin Arthritis Rheum"},{"key":"804_CR33","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158:1131\u201341. https:\/\/doi.org\/10.1001\/jamadermatol.2022.2909.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"804_CR34","doi-asserted-by":"publisher","first-page":"953","DOI":"10.5114\/ada.2022.120886","volume":"39","author":"H Fu","year":"2022","unstructured":"Fu H, Guo J. Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies. Adv Dermatol Allergol. 2022;39(5):953\u20138. https:\/\/doi.org\/10.5114\/ada.2022.120886.","journal-title":"Adv Dermatol Allergol"},{"key":"804_CR35","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Thaci D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase\u00a03 trial. Lancet. 2019;394:576\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(19)30952-3.","journal-title":"Lancet"},{"key":"804_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase\u00a0III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041.","journal-title":"J Am Acad Dermatol"},{"key":"804_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase\u00a0III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042.","journal-title":"J Am Acad Dermatol"},{"key":"804_CR38","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003\u20132011. JAMA Dermatol. 2013;149:1180\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2013.5264.","journal-title":"JAMA Dermatol"},{"key":"804_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa070","volume":"4","author":"K Geale","year":"2020","unstructured":"Geale K, Lindberg I, Paulsson EC, et al. Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract. 2020;4:rkaa070. https:\/\/doi.org\/10.1093\/rap\/rkaa070.","journal-title":"Rheumatol Adv Pract"},{"key":"804_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02417-x","volume":"23","author":"A Haddad","year":"2021","unstructured":"Haddad A, Gazitt T, Feldhamer I, et al. Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther. 2021;23:44. https:\/\/doi.org\/10.1186\/s13075-021-02417-x.","journal-title":"Arthritis Res Ther"},{"key":"804_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2349658","volume":"35","author":"M Zhdanava","year":"2024","unstructured":"Zhdanava M, Fitzgerald T, Pilon D, et al. Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States. J Dermatol Treat. 2024;35:2349658. https:\/\/doi.org\/10.1080\/09546634.2024.2349658.","journal-title":"J Dermatol Treat"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00804-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00804-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00804-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:52:32Z","timestamp":1768834352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00804-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00804-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Philip J Mease has received research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, and UCB; consulting fees from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Century, Cullinan, Eli Lilly, Inmagene, Johnson & Johnson, Novartis, Pfizer, Spyre, Takeda, and UCB; and speaker fees from AbbVie, Amgen, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB. Jessica Walsh received research funding from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Eli Lilly, Johnson & Johnson, Novartis, and UCB. Timothy P Fitzgerald, Soumya D Chakravarty, and Elizabeth Adamson are employees of and own stock in Johnson & Johnson. Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, and Dominic Pilon are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Johnson & Johnson, which funded the development and conduct of this study. Shikha Singla received research funding from Eli Lilly and consulting fees from AbbVie, Janssen and UCB; and speaker fees from Johnson & Johnson. Joseph F Merola is a consultant and\/or investigator for AbbVie, Amgen, Astra Zeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Johnson & Johnson Leo Pharma, Moonlake, Novartis, Pfizer, Sanofi-Regeneron, Sun Pharma, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The IQVIA PharMetrics\n                      \u00ae\n                      Plus database was used under license. All data were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA); therefore, institutional review board review was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}